Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-center, Open-label Study to Evaluate the Safety and Efficacy of VGT-309, a Tumor-Targeted, Activatable Fluorescent Imaging Agent, in Subjects Undergoing Surgery for Cancer in the Lung

NCT06145048 is registered in ClinicalTrials.gov with Vergent Bioscience, Inc. as lead sponsor.

NCT NCT06145048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06145048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-center, Open-label Study to Evaluate the Safety and Efficacy of VGT-309, a Tumor-Targeted, Activatable Fluorescent Imaging Agent, in Subjects Undergoing Surgery for Cancer in the Lung
Lead sponsor
Vergent Bioscience, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 5, 2023
Completion date
February 20, 2025
Enrollment
89 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, lung metastases